Keryx Biopharmaceuticals, Inc. (KERX)
From ValueWiki
Keryx Biopharmaceuticals is a biotechnology company that is focused in the development, acquisition and commercialization of pharmaceutical therapies for life threatening diseases, mainly diabetes and cancer. [1]
Contents |
|
|
Snapshot
This section needs content! Click the blue edit link (to the right) to contribute.
Recent Events
More News...== Future Events ==This section needs content! Click the blue edit link (to the right) to contribute.
Leadership
- Michael S. Weiss (Chairman and Chief Executive Officer)
- I. Craig Henderson, MD (President)
- Ronald C. Renaud, Jr. (Chief Financial Officer, Treasurer & Investor Relations)
More info in Reuters
Risks
- Company is still cash flow negative
- There are significant risks associated with clinical trials.
- There is no guarantee that regulatory bodies, such as FDA in the US will approve the companies' drug candidates.
- Review process for New Drug Application might take significantly longer than expected.
- Even if a drug is approved, there is risk that the regulatory bodies might revoke the approval due to unforeseen situation.
More information on risks can be found in the company's 10-k
History
This section needs content! Click the blue edit link (to the right) to contribute.
Fundamentals
Technical Analysis
This section needs content! Click the blue edit link (to the right) to contribute.
Official Links
- Company homepage
- Information about ongoing clinical trials
- Sulonex
- Zerenex
- KRX-0401 (Perifosine), in colaboration with Aeterna Zentaris (AEZS)
Research Links
This section needs content! Click the blue edit link (to the right) to contribute.
Rumors
Discuss rumors on the Talk Page and link to the topics here.
Message Boards
Options
- Options Prices and Data at Yahoo Finance
- Options Prices and Data at IVolatility.com
- Call Options Data at OptionsBuddy.com
Notes
- ↑ http://www.keryx.com/pages.cfm?pg=au-co Company Website
